Clinical Trial Update: Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating safety, tolerability, and immune response of the ACAM3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in adults;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine (Modified Vaccinia Ankara (MVA) smallpox vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Smallpox | Phase 1 | Status: COMPLETED